GLYCAN THERAPEUTICS CORPORATION
- RALEIGH, NC 27606-6330
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
GLYCAN THERAPEUTICS CORPORATION has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About GLYCAN THERAPEUTICS CORPORATION
- Headquarters
- RALEIGH, NC 27606-6330
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIKYG3DZSMH4R7
- CAGE6XZ77
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 23 awards
- Total awarded
- $24,774,511
- By phase
- SBIR Phase II: 9
- SBIR Phase I: 8
- STTR Phase I: 5
- STTR Phase II: 1
- By agency
- Department of Health and Human Services: 23
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 3
- 2023: 6
- 2022: 2
- 2021: 2
- 2020: 2
- 2019: 3
- 2018: 1
- 2017: 2
- 2015: 1
- 2013: 1
Awards (most recent first)
Development of anticoagulant sulfated glycans
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,151,736
Sep 20, 2024 – Aug 31, 2026
Solicitation PA22-176 (2022) · Topic 300
Development of dekaparin to replace animal-sourced heparin
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,738,492
Sep 17, 2024 – Jun 30, 2026
Solicitation HL23-009 (2023) · Topic NHLBI
Synthesis of the library of heparan sulfate hexasaccharide mimetics
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,150,944
Sep 15, 2024 – Sep 14, 2026
Solicitation PA22-176 (2022) · Topic 300
Synthesis of the library of heparan sulfate hexasaccharide mimetics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $255,001
Sep 21, 2023 – Mar 21, 2024
Solicitation PA22-176 (2022) · Topic 300
Development of heparan sulfate-based therapeutics to treat inflammatory diseases
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,387,583
Sep 6, 2023 – Jul 31, 2026
Solicitation PA20-272 (2020) · Topic 300
Sulfated Carbohydrates for the Treatment of Periodontitis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $347,537
Sep 1, 2023 – Aug 31, 2024
Solicitation PA22-178 (2022) · Topic NIDCR · Research partner: UNIV OF NORTH CAROLINA CHAPEL HILL
Development of anticoagulant sulfated glycans
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $355,989
Aug 16, 2023 – Feb 15, 2024
Solicitation PA22-176 (2022) · Topic 300
National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $603,924
Jul 1, 2023 – Jun 30, 2024
Solicitation PAR22-073 (2022) · Topic 102 · Research partner: UNIV OF NORTH CAROLINA CHAPEL HILL
Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $350,000
Feb 1, 2023 – Jan 31, 2024
Solicitation PA21-259 (2021) · Topic 300
Development of analytical methods for glycosaminoglycans from biological sources
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,977,542
Sep 17, 2022 – Aug 31, 2024
Solicitation PA21-259 (2021) · Topic 300
Construction of chondroitin sulfate microarray
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $331,634
May 1, 2022 – Jan 31, 2023
Solicitation PA21-259 (2021) · Topic 300
Quantitative analysis of heparan sulfate using 13C-labeled standards
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $300,000
Sep 15, 2021 – May 14, 2022
Solicitation PA20-260 (2020) · Topic 300
Development of heparan sulfate-based therapeutics to treat inflammatory diseases
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $231,139
Sep 14, 2021 – May 31, 2022
Solicitation PA20-260 (2020) · Topic 300
Developing Heparan Sulfate Glycan Array
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,411,727
May 1, 2020 – Apr 30, 2022
Solicitation PA19-272 (2019) · Topic 300
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,702,800
Mar 1, 2020 – Feb 28, 2022
Solicitation PA20-272 (2019) · Topic 300
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $536,791
Aug 1, 2019 – Feb 29, 2020
Solicitation PA18-574 (2018) · Topic 300
Development of a New Carbohydrate-based Anticoagulant Drug
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,493,273
Jul 4, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NHLBI
LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,599,559
Dec 1, 2018 – Nov 30, 2020
Solicitation PA18-591 (2018) · Topic 300 · Research partner: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reactor for Insect Cell Culture
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $334,239
May 1, 2018 – Oct 31, 2018
Solicitation PA18-591 (2017) · Topic 300 · Research partner: UNIV OF NORTH CAROLINA CHAPEL HILL
Developing Heparan Sulfate Glycan Array
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $296,746
Sep 1, 2017 – Aug 31, 2019
Solicitation PA16-158 (2016) · Topic NIGMS · Research partner: UNIV OF NORTH CAROLINA CHAPEL HILL
Development of a New Carbohydrate based Anticoagulant Drug
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $224,698
Aug 1, 2017 – Jul 31, 2018
Solicitation PA16-303 (2016) · Topic NHLBI · Research partner: UNIV OF NORTH CAROLINA CHAPEL HILL
CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $693,710
Solicitation year 2017 · Topic NCI
CHEMOENZYMATIC SYNTHESIS OF HEPARIN SULFATE OLIGOSACCARIDES
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $299,447
Solicitation year 2013 · Topic NCI · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325414Biological Product (except Diagnostic) ManufacturingPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with GLYCAN THERAPEUTICS CORPORATION?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.